Key Points
- Perceptive Advisors sold large blocks of Lyra stock across Nov. 6–13, including 31,810 shares on Nov. 13 at $3.90, reducing its stake by 69.40% to 14,026 shares.
- Lyra reported Q3 EPS of ($3.38), beating the -$5.98 estimate but missing on revenue ($0.03M vs. $0.21M expected); the stock traded at $3.90 (near its 12‑month low) and carries an average analyst rating of "Reduce".
Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) major shareholder Perceptive Advisors Llc sold 5,320 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $4.31, for a total value of $22,929.20. Following the completion of the sale, the insider directly owned 18,122 shares of the company's stock, valued at approximately $78,105.82. This represents a 22.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Perceptive Advisors Llc also recently made the following trade(s):
- On Thursday, November 13th, Perceptive Advisors Llc sold 31,810 shares of Lyra Therapeutics stock. The shares were sold at an average price of $3.90, for a total transaction of $124,059.00.
- On Wednesday, November 12th, Perceptive Advisors Llc sold 8,745 shares of Lyra Therapeutics stock. The stock was sold at an average price of $4.06, for a total transaction of $35,504.70.
- On Monday, November 10th, Perceptive Advisors Llc sold 18,502 shares of Lyra Therapeutics stock. The shares were sold at an average price of $4.54, for a total transaction of $83,999.08.
- On Friday, November 7th, Perceptive Advisors Llc sold 19,739 shares of Lyra Therapeutics stock. The stock was sold at an average price of $4.75, for a total transaction of $93,760.25.
- On Thursday, November 6th, Perceptive Advisors Llc sold 32,149 shares of Lyra Therapeutics stock. The stock was sold at an average price of $5.18, for a total value of $166,531.82.
Lyra Therapeutics Trading Up 2.0%
NASDAQ LYRA traded up $0.08 on Friday, reaching $3.90. The stock had a trading volume of 40,232 shares, compared to its average volume of 217,146. Lyra Therapeutics, Inc. has a 1 year low of $3.69 and a 1 year high of $37.50. The business has a 50 day moving average price of $6.35 and a 200 day moving average price of $7.81. The company has a market capitalization of $6.39 million, a price-to-earnings ratio of -0.17 and a beta of 0.10.
Lyra Therapeutics (NASDAQ:LYRA - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($3.38) earnings per share for the quarter, topping analysts' consensus estimates of ($5.98) by $2.60. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.21 million. Lyra Therapeutics had a negative return on equity of 566.15% and a negative net margin of 5,491.17%. On average, analysts anticipate that Lyra Therapeutics, Inc. will post -0.93 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have commented on LYRA. Weiss Ratings reissued a "sell (e+)" rating on shares of Lyra Therapeutics in a research report on Wednesday, October 8th. HC Wainwright restated a "neutral" rating on shares of Lyra Therapeutics in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Reduce" and an average target price of $100.00.
Read Our Latest Research Report on Lyra Therapeutics
Institutional Inflows and Outflows
An institutional investor recently raised its position in Lyra Therapeutics stock. Bank of America Corp DE lifted its stake in Lyra Therapeutics, Inc. (NASDAQ:LYRA - Free Report) by 33.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,542 shares of the company's stock after acquiring an additional 7,190 shares during the period. Bank of America Corp DE owned approximately 1.74% of Lyra Therapeutics worth $256,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 95.62% of the company's stock.
Lyra Therapeutics Company Profile
(
Get Free Report)
Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
